It sounds misleading for Cyclacel's management to state that elderly AML patients presently have only 10% survival at end of one year with current standard of care treatment.
a) Their own slides from RR conference webcast show a survival curve that shows around 25% survival at end of one year on current standard of care (see slide9)
b) Clolar (Genzyme) therapy that got rejected by FDA panel showed 40% survival at end of one year.
c) Other independent studies have put survival in elderly AML in 30%-50% range.
So I am confused why management would claim that there is only 10% survival with current standard of care. Please advise.
I know, but this time it is different, Thestreet usually bashes bio tech stocks while they are shorting it. but they can't short CYCC right now so they are going to pump it and then short the hell out of it and then buy the shares back directly from CYCC as a "private" investor. same sh!t different toilet...
Your really don't want anyone even remotely associated with TSCM getting near this company. They are always "the kiss of death" to a stock. That's over 10 years of trading/investing talking.
Thank you, this is a clear winner, the way the stock is behaving is a good enough proof, add the insider buys, all the info we have about AML in elderly patients, the tiny float, the absolutely none existent short interest, and the pumping we are going to get from ADAM F. (thestreet.com)and you will see that this is one of the best plays you can get into for the next few months.
"Current treatment options in elderly patients with AML
considered unsuitable for standard intensive chemotherapy
include low-dose cytarabine (ara-C), best supportive care, and
investigational agents. Treatment outcome with low-dose ara-C
typically results in a median survival of <3 months.
also please note that the graph above is Age ranged from 61 to 85 years, sapacitabine is 70+
Here is more statistics about AML
Do the math and you will see that a 20%+ survival rate with Sapacitabine in the 70+ aged patience is huge...
i agree with you about my poor choice of words for subject line.
however, i am certain that elderly AML patients have >>20% one-year survival, and not 10% survival as management would like you to believe. do you have any independent link that shows that elderly AML patients do have just 10% survival at 1-year mark with current standard of care.